![]() |
SINGAPORE, Aug. 21, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today revealed that targeted pre-launch scientific outreach maximizes medical affairs teams' impact on treatment adoption in the latest Veeva Pulse Field Trends Report. The analysis shows biopharmas investing in pre-launch scientific activities and prioritizing congresses gain 40% faster treatment adoption than those that invested less. Early-career experts are also more open to digital engagement and four times more likely to start patients on a new treatment.
Register to read this story and more for free.
Signing up for an account helps us improve your browsing experience.
ContinueOR
See our subscription options.
Already have an account? Log in here